Triphase Accelerator Accelerator Corporation Announces New Collaboration With Celgene
TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced a new strategic collaboration with Celgene Corporation. The new agreement provides Celgene with the option to acquire a novel bi-specific antibody that Triphase licensed from PharmAbcine. The bi-specific antibody targets VEGFR-2/TIE 2 and is currently in preclinical studies.
“We have made important progress in our existing collaboration with Celgene, and now expand the collaboration with the addition of a bi-specific antibody,” said Frank Stonebanks, founder, president and CEO of Triphase. “This option agreement and collaboration with Celgene provides us with the resources to study a novel drug and explore the potential to make a meaningful difference in the treatment of cancer with high unmet medical needs.”
Help employers find you! Check out all the jobs and post your resume.
“We have made important progress in our existing collaboration with Celgene, and now expand the collaboration with the addition of a bi-specific antibody,” said Frank Stonebanks, founder, president and CEO of Triphase. “This option agreement and collaboration with Celgene provides us with the resources to study a novel drug and explore the potential to make a meaningful difference in the treatment of cancer with high unmet medical needs.”
Help employers find you! Check out all the jobs and post your resume.